dc.contributor.author
Sanz-Gómez, Marta
dc.contributor.author
Aledavood, Elnaz
dc.contributor.author
Beroiz-Salaverri, Marina
dc.contributor.author
Lagartera, Laura
dc.contributor.author
Vega-Martín, Elena
dc.contributor.author
Gil-Ortega, Marta
dc.contributor.author
Cumella, José
dc.contributor.author
Pérez, Concepción
dc.contributor.author
Luque Garriga, F. Xavier
dc.contributor.author
Estarellas, Carolina
dc.contributor.author
Fernández-Alfonso, María S.
dc.contributor.author
Castro, Ana
dc.date.issued
2022-04-28T10:10:19Z
dc.date.issued
2022-04-28T10:10:19Z
dc.date.issued
2022-03-10
dc.date.issued
2022-04-28T10:10:19Z
dc.identifier
https://hdl.handle.net/2445/185195
dc.description.abstract
Endothelial adenosine monophosphate-activated protein kinase (AMPK) plays a critical role in the regulation of vascular tone through stimulating nitric oxide (NO) release in endothelial cells. Since obesity leads to endothelial dysfunction and AMPK dysregulation, AMPK activation might be an important strategy to restore vascular function in cardiometabolic alterations. Here, we report the identification of a novel AMPK modulator, the indolic derivative IND6, which shows affinity for AMPKα1β1γ1, the primary AMPK isoform in human EA.Hy926 endothelial cells. IND6 shows inhibitory action of the enzymatic activity in vitro, but increases the levels of p-Thr174AMPK, p-Ser1177eNOS and p-Ser79ACC in EA.Hy926. This paradoxical finding might be explained by the ability of IND6 to act as a mixed-type inhibitor, but also to promote the enzyme activation by adopting two distinct binding modes at the ADaM site. Moreover, functional assays reveal that IND6 increased the eNOS-dependent production of NO and elicited a concentration-dependent vasodilation of endothelium-intact rat aorta due to AMPK and eNOS activation, demonstrating a functional activation of the AMPK-eNOS-NO endothelial pathway. This kinase inhibition profile, combined with the paradoxical AMPK activation in cells and arteries, suggests that these new chemical entities may constitute a valuable starting point for the development of new AMPK modulators with therapeutic potential for the treatment of vascular complications associated with obesity.
dc.format
application/pdf
dc.publisher
Nature Publishing Group
dc.relation
Reproducció del document publicat a: https://doi.org/10.1038/s41598-022-07077-8
dc.relation
Scientific Reports, 2022, vol. 12, p. 4225
dc.relation
https://doi.org/10.1038/s41598-022-07077-8
dc.rights
cc-by (c) Sanz-Gómez, Marta et al., 2022
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)
dc.subject
Inhibidors enzimàtics
dc.subject
Enzyme inhibitors
dc.title
Novel indolic AMPK modulators induce vasodilatation through activation of the AMPK-eNOS-NO pathway
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion